Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
December-2022 Volume 24 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
December-2022 Volume 24 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML

  • Supplementary Files
    • Supplementary_Data.pdf
Article Open Access

Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently

  • Authors:
    • Chao-Shun Chan
    • Fong-Jhih Lin
    • Chih-Min Liu
    • Yung-Kuo Lin
    • Yao-Chang Chen
    • Chun-Chun Hsu
    • Satoshi Higa
    • Shih-Ann Chen
    • Yi-Jen Chen
  • View Affiliations / Copyright

    Affiliations: Department of Internal Medicine, Division of Cardiology, Taipei Medical University Hospital, Taipei 11031, Taiwan, R.O.C., Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan, R.O.C., Department of Medicine, Division of Cardiology, Heart Rhythm Center, Taipei Veterans General Hospital, Taipei 11217, Taiwan, R.O.C., Department of Internal Medicine, Division of Cardiology, School of Medicine, Taipei Medical University, Taipei 11031, Taiwan, R.O.C., Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490, Taiwan, R.O.C., School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan, R.O.C., Cardiac Electrophysiology and Pacing Laboratory, Division of Cardiovascular Medicine, Makiminato Central Hospital, Okinawa 9012131, Japan, Department of Internal Medicine, Division of Cardiology, Wan‑Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan, R.O.C.
    Copyright: © Chan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 720
    |
    Published online on: October 18, 2022
       https://doi.org/10.3892/etm.2022.11656
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Mirabegron increases atrial fibrillation (AF) risk. The left atrium (LA) is the most critical ‘substrate’ for AF and has higher arrhythmogenesis compared with the right atrium (RA). The present study aimed to investigate the electrophysiological and arrhythmogenic effects of mirabegron on the LA and RA and clarify the potential underlying mechanisms. Conventional microelectrodes, a whole‑cell patch clamp and a confocal microscope were used in rabbit LA and RA preparations or single LA and RA myocytes before and after mirabegron administration with or without cotreatment with KT5823 [a cyclic adenosine monophosphate (cAMP)‑dependent protein kinase inhibitor]. The baseline action potential duration at repolarization extents of 20 and 50% (but not 90%) were shorter in the LA than in the RA. Mirabegron at 0.1 and 1 µM (but not 0.01 µM) reduced the action potential duration at repolarization extents of 20 and 50% in the LA and RA. Mirabegron (0.1 µM) increased the occurrence of tachypacing‑induced burst firing in the LA but not in the RA, where it was suppressed by KT5823 (1 µM). Mirabegron (0.1 µM) increased the L‑type Ca2+ current (ICa‑L), ultrarapid component of delayed rectifier K+ current (IKur), Ca2+ transients and sarcoplasmic reticulum Ca2+ content but reduced transient outward K+ current (Ito) in the LA myocytes. However, mirabegron did not change the Na+ current and delayed rectifier K+ current in the LA myocytes. Moreover, pretreatment with KT5823 (1 µM) inhibited the effects of mirabegron on ICa‑L, Ito and IKur in the LA myocytes. Furthermore, in the RA myocytes, mirabegron reduced ICa‑L but did not change Ito. In conclusion, mirabegron differentially regulates electrophysiological characteristics in the LA and RA. Through the activation of the cAMP‑dependent protein kinase pathway and induction of Ca2+ dysregulation, mirabegron may increase LA arrhythmogenesis, leading to increased AF risk.
View Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

View References

1 

Gauthier C, Tavernier G, Charpentier F, Langin D and Le Marec H: Functional β3-adrenoceptor in the human heart. J Clin Invest. 98:556–562. 1996.PubMed/NCBI View Article : Google Scholar

2 

Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, et al: Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial. Eur Urol. 63:283–295. 2013.PubMed/NCBI View Article : Google Scholar

3 

Wagg A, Cardozo L, Nitti VW, Castro-Diaz D, Auerbach S, Blauwet MB and Siddiqui E: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 43:666–675. 2014.PubMed/NCBI View Article : Google Scholar

4 

Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM and Schermer CR: Efficacy, safety, and tolerability of mirabegron in patients aged ≥ 65yr with overactive bladder wet: A phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 77:211–220. 2020.PubMed/NCBI View Article : Google Scholar

5 

Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL and Marec HL: The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest. 102:1377–1384. 1998.PubMed/NCBI View Article : Google Scholar

6 

Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C and Balligand JL: Upregulation of beta3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 103:1649–1655. 2001.PubMed/NCBI View Article : Google Scholar

7 

Skeberdis VA, Gendvilienė C, Zablockaitė D, Treinys R, Macianskiene R, Bogdelis A, Jurevicius J and Fischmeister R: β3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest. 118:3219–3227. 2008.PubMed/NCBI View Article : Google Scholar

8 

Nitti VW, Khullar V, Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E and Martin NE: Mirabegron for the treatment of overactive bladder: A prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 67:619–632. 2013.PubMed/NCBI View Article : Google Scholar

9 

Batista JE, Kölbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, Coppell A, Kaper M, Huang M and Siddiqui E: The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 7:167–179. 2015.PubMed/NCBI View Article : Google Scholar

10 

Nitti VW, Chapple CR, Walters C, Blauwet MB, Herschorn S, Milsom I, Auerbach S and Radziszewski P: Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: Results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial. Int J Clin Pract. 68:972–985. 2014.PubMed/NCBI View Article : Google Scholar

11 

Lindemann JP, Jones LR, Hathaway DR, Henry BG and Watanabe AM: β-Adrenergic stimulation of phospholamban phosphorylation and Ca2+-ATPase activity in guinea pig ventricles. J Biol Chem. 258:464–471. 1983.PubMed/NCBI

12 

Takasago T, Imagawa T and Shigekawa M: Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J Biochem. 106:872–877. 1989.PubMed/NCBI View Article : Google Scholar

13 

Perchenet L, Hinde AK, Patel KC, Hancox JC and Levi AJ: Stimulation of Na+/Ca2+ exchange by the β-adrenergic/protein kinase A pathway in guinea-pig ventricular myocytes at 37 degrees C. Pflugers Arch. 439:822–828. 2000.PubMed/NCBI View Article : Google Scholar

14 

Lou Q, Janardhan A and Efimov IR: Remodeling of calcium handling in human heart failure. Adv Exp Med Biol. 740:1145–1174. 2012.PubMed/NCBI View Article : Google Scholar

15 

Heijman J, Voigt N, Wehrens XH and Dobrev D: Calcium dysregulation in atrial fibrillation: the role of CaMKII. Front Pharmacol. 5(30)2014.PubMed/NCBI View Article : Google Scholar

16 

Pappone C, Rosanio S, Oreto G, Tocchi M, Gugliotta F, Vicedomini G, Salvati A, Dicandia C, Mazzone P, Santinelli V, et al: Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation. 102:2619–2628. 2000.PubMed/NCBI View Article : Google Scholar

17 

Roithinger FX, Steiner PR, Goseki Y, Sparks PB and Lesh MD: Electrophysiologic effects of selective right versus left atrial linear lesions in a canine model of chronic atrial fibrillation. J Cardiovasc Electrophysiol. 10:1564–1574. 1999.PubMed/NCBI View Article : Google Scholar

18 

Lin YK, Lai MS, Chen YC, Cheng CC, Huang JH, Chen SA, Chen YJ and Lin CI: Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci. 122:121–132. 2012.PubMed/NCBI View Article : Google Scholar

19 

Chan CS, Lin YK, Chen YC, Kao YH, Chen SA and Chen YJ: Hydrogen sulphide increases pulmonary veins and atrial arrhythmogenesis with activation of protein kinase C. J Cell Mol Med. 22:3503–3513. 2018.PubMed/NCBI View Article : Google Scholar

20 

Chan CS, Lin YS, Lin YK, Chen YC, Kao YH, Hsu CC, Chen SA and Chen YJ: Atrial arrhythmogenesis in a rabbit model of chronic obstructive pulmonary disease. Transl Res. 223:25–39. 2020.PubMed/NCBI View Article : Google Scholar

21 

National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the care and use of laboratory animals. 8th edition. National Academies Press (US), Washington, DC, 2011.

22 

Chan CS, Chen YC, Chang SL, Lin YK, Kao YH, Chen SA and Chen YJ: Heart failure differentially modulates the effects of ivabradine on the electrical activity of the sinoatrial node and pulmonary veins. J Card Fail. 24:763–772. 2018.PubMed/NCBI View Article : Google Scholar

23 

Calvo-Guirado JL, Satorres M, Negri B, Ramirez-Fernandez P, Maté-Sánchez JE, Delgado-Ruiz R, Gomez-Moreno G, Abboud M and Romanos GE: Biomechanical and histological evaluation of four different titanium implant surface modifications: An experimental study in the rabbit tibia. Clin Oral Invest. 18:1495–1505. 2014.PubMed/NCBI View Article : Google Scholar

24 

Chen YJ, Chen YC, Wongcharoen W, Lin CI and Chen SA: Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes. Br J Pharmacol. 153:915–925. 2008.PubMed/NCBI View Article : Google Scholar

25 

Lu YY, Chung FB, Chen YC, Tsai CF, Kao YH, Chao TF, Huang JH, Chen SA and Chen YJ: Distinctive electrophysiological characteristics of right ventricular outflow tract cardiomyocytes. J Cell Mol Med. 18:1540–1548. 2014.PubMed/NCBI View Article : Google Scholar

26 

Huang SY, Lu YY, Lin YK, Chen YC, Chen YA, Chung CC, Lin WS, Chen SA and Chen YJ: Ceramide modulates electrophysiological characteristics and oxidative stress of pulmonary vein cardiomyocytes. Eur J Clin Invest. 52(e13690)2022.PubMed/NCBI View Article : Google Scholar

27 

McDonald TF, Pelzer S, Trautwein W and Pelzer DJ: Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev. 74:365–507. 1994.PubMed/NCBI View Article : Google Scholar

28 

Landstrom AP, Dobrev D and Wehrens XHT: Calcium signaling and cardiac arrhythmias. Circ Res. 120:1969–1993. 2017.PubMed/NCBI View Article : Google Scholar

29 

Li D, Zhang L, Kneller J and Nattel S: Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res. 88:1168–1175. 2001.PubMed/NCBI View Article : Google Scholar

30 

Grand AO: Cardiac ion channels. Circ Arrhythm Electrophysiol. 2:185–194. 2009.PubMed/NCBI View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Chan C, Lin F, Liu C, Lin Y, Chen Y, Hsu C, Higa S, Chen S and Chen Y: Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently. Exp Ther Med 24: 720, 2022.
APA
Chan, C., Lin, F., Liu, C., Lin, Y., Chen, Y., Hsu, C. ... Chen, Y. (2022). Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently. Experimental and Therapeutic Medicine, 24, 720. https://doi.org/10.3892/etm.2022.11656
MLA
Chan, C., Lin, F., Liu, C., Lin, Y., Chen, Y., Hsu, C., Higa, S., Chen, S., Chen, Y."Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently". Experimental and Therapeutic Medicine 24.6 (2022): 720.
Chicago
Chan, C., Lin, F., Liu, C., Lin, Y., Chen, Y., Hsu, C., Higa, S., Chen, S., Chen, Y."Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently". Experimental and Therapeutic Medicine 24, no. 6 (2022): 720. https://doi.org/10.3892/etm.2022.11656
Copy and paste a formatted citation
x
Spandidos Publications style
Chan C, Lin F, Liu C, Lin Y, Chen Y, Hsu C, Higa S, Chen S and Chen Y: Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently. Exp Ther Med 24: 720, 2022.
APA
Chan, C., Lin, F., Liu, C., Lin, Y., Chen, Y., Hsu, C. ... Chen, Y. (2022). Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently. Experimental and Therapeutic Medicine, 24, 720. https://doi.org/10.3892/etm.2022.11656
MLA
Chan, C., Lin, F., Liu, C., Lin, Y., Chen, Y., Hsu, C., Higa, S., Chen, S., Chen, Y."Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently". Experimental and Therapeutic Medicine 24.6 (2022): 720.
Chicago
Chan, C., Lin, F., Liu, C., Lin, Y., Chen, Y., Hsu, C., Higa, S., Chen, S., Chen, Y."Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently". Experimental and Therapeutic Medicine 24, no. 6 (2022): 720. https://doi.org/10.3892/etm.2022.11656
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team